News, Stories, Guidelines, Opinions, History

Disparities in use of hereditary genetic testing in triple-negative breast cancer

Hereditary DNA testing is recommended for all patients with Triple-Negative Breast Cancer (TNBC) to identify inherited BRCA1/BRCA2 mutations responsible for developing breast cancer and to help physicians in managing their patients’ treatment. To see who is being tested, researchers analyzed the medical records of 1,318 women diagnosed between 2017 and 2021  treated in US community oncology clinics with active genetic screening programs.

More likely to be tested were Hispanic women (82%), White women (77%) and patients in the Western and Northeastern United States. Less likely to be treated were Black women (67%), poorer patients, and those living in the Midwest and South.

“Further research should be performed to understand reasons why testing was not done, to address barriers, the researchers concluded.

Scroll to Top